Navigation Links
Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
Date:4/10/2013

delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

About USAMRIID

USAMRIID's mission is to protect the warfighter from biological threats and to be prepared to investigate disease outbreaks or threats to public health. Research conducted at USAMRIID leads to medical solutions—vaccines, drugs, diagnostics, and information—that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

[The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official  endorsement should be inferred.]

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical result
'/>"/>

SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
2. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Inovio Pharmaceuticals to Present at SPI 2012
4. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
5. Inovio Pharmaceuticals to Present at JMP Investor Conference
6. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
7. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
8. Inovio Pharmaceuticals Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Inovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
10. Inovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
11. Inovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Drug Administration (FDA) has removed the clinical hold ... SWOG,s ongoing Phase 1b/2 clinical trial (S1313). The ... PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with ... pancreatic adenocarcinoma.  The study will resume under a ...
(Date:9/18/2014)... , September 18, 2014 After 6 ... community, we,re finally here - the new programme for the ... 2015, part of our global Cool Chain series, has just ... here ! As the lines between supply chain, ... together a programme that is broad and yet specific, focused ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... Becomes Squarer, Makes You Look Older, ASPS,Study Reveals, ... giving away your age, and it has nothing to ... in January,s Plastic and,Reconstructive Surgery(R) (PRS), the official medical ... that as we age, the,lower jaw continues to grow, ...
... Inc.,today announced that a paper published in ... reports that SF1126, the company,s lead product,candidate, ... paper, entitled "A Vascular Targeted Pan Phosphoinositide ... Activity," is,based on preclinical studies conducted by ...
Cached Medicine Technology:Looking Older? How Square is Your Jaw Line? 2Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... antidepressant can quickly alter the way brain cells communicate with ... Sept. 18 in Current Biology , are a ... antidepressants. Experts said the hope is to eventually be able ... from a drug -- and which people would fare better ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
(Date:9/18/2014)... convene a one-day conference at the Milken Institute School ... September 25, 2014 to discuss the Global Health Security ... purpose of this event is to invite discussion of ... years, including action plans to curtail the current deadly ... GHSA, international organizations and more than 50 countries have ...
(Date:9/18/2014)... N.C. Dangerous new pathogens such as the Ebola ... ancient scourges such as the bubonic plague are still ... responds to infections. , In a study published online ... researchers at Duke Medicine and Duke-NUS Graduate Medical School ... bubonic plague hitchhike on immune cells in the lymph ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:New insights on an ancient plague could improve treatments for infections 2
... Orissa government has ordered administrations of all 30 districts to ... three days.// ,The officials were Thursday asked to ... senior health department official. ,These would then be ... government does not have testing facilities to confirm the presence ...
... safety lawyer, writes about why it is essential for us ... that there is a major defect in the food safety ... people affected or even killed by contaminated food products from ... it prevents our society from knowing the source of our ...
... of NSAID by women in their first trimester could ... ,Non-steroidal anti-inflammatory drugs, NSAIDs, Cardiac septal defects, Journal ... Congenital abnormality, Diabetes ,Women who take non-steroidal ... more likely to give birth to babies with congenital ...
... say that a commonly used HIV drug may be useful ... be used in prevention of the cancer and could be ... and his colleagues said that such a cream could prove ... lesions. However no clinical trials have begun as yet. ...
... hundreds of resident doctors in Delhi who had gone on ... agitation //for the next three months with the reservation bill ... the parliament has referred the reservation bill to the standing ... being. The bill will be placed in the floor of ...
... the University of Pennsylvania have disclosed that a specific ... of changing into bone, muscle, neurons or other// types ... environment. , ,The researchers found that ... bone marrow, are soliciting tangible clues from their local ...
Cached Medicine News:Health News:Importance of knowing the source of our food 2Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Medicos Suspends Anti-quota Stir 2Health News:Adult stem cells are sensitive to responses from the environment 2
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Medicine Products: